Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | FADS1 | O60427 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8664436 | 1.00 | PDPK1 (0.66) | PDPK1CA1CA2SLC18A3MAOA | |
| SCHEMBL6344102 | 0.88 | HTT (0.59) | TAS1R3TAS1R1TAS1R2HTTALDH1A1 | |
| SCHEMBL2322457 | 0.83 | PDPK1 (0.70) | PDPK1CA1CA2SLC18A3MAOA | |
| Hydrochloric Acid SCHEMBL7123292 | 0.81 | PDPK1 (0.68) | PDPK1CA1CA2SLC18A3MAOA | |
| SCHEMBL19508305 | 0.79 | PDPK1 (0.66) | PDPK1CA1CA2SLC18A3MAOA | |
| SCHEMBL20354303 | 0.79 | PDPK1 (0.66) | PDPK1CA1CA2SLC18A3MAOA | |
| SCHEMBL61508 | 0.79 | PDPK1 (1.00) | PDPK1CA1CA2SLC18A3MAOA | |
| SCHEMBL1488037 | 0.79 | PDPK1 (0.66) | PDPK1CA1CA2SLC18A3MAOA | |
| SCHEMBL6850366 | 0.79 | PDPK1 (0.66) | PDPK1CA1CA2SLC18A3MAOA | |
| SCHEMBL13618841 | 0.79 | PDPK1 (0.66) | PDPK1CA1CA2SLC18A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517103-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2019-07-31 | — | — | EP | disclosed |
| EP-2531181-B1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD (IL) | 2019-04-10 | — | — | EP | disclosed |
| CN-102791258-B | Alleviating prolongation delivery formulations of Rasagiline and application thereof | 图必制药公司 | 2018-05-08 | — | — | CN | disclosed |
| US-9943489-B2 | Extended release formulations of rasagiline and uses thereof | PHARMATWOB LTD. (IL) | 2018-04-17 | — | — | US | disclosed |
| EP-2531181-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2012-12-12 | — | — | EP | disclosed |
| US-20120301542-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2012-11-29 | — | — | US | disclosed |
| WO-2011095973-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2011-08-11 | — | — | WO | disclosed |
| EP-1796675-A4 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| EP-1796675-A2 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006039252-A2 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-6127388-A | Azetidine, pyrrolidine and piperidine derivatives as 5-HT1D receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 2000-10-03 | — | — | US | disclosed |
| US-5998440-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARPE & DOHME LTD. (GB) | 1999-12-07 | — | — | US | disclosed |
| EP-0906308-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5-HT1D RECEPTOR AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
| WO-1997045426-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5-HT1D RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-04 | — | — | WO | disclosed |
| EP-0804434-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | CXCL12, CXCR4, CX3CR1 | PDPK1 670/4885CA1 2858/4885CA2 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.